SAN DIEGO, CA / ACCESS Newswire / September 9, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing ...
Revelation Biosciences (REVB) announced successful submission and acceptance of the end-of-phase 1 meeting package to FDA and that the company is ...
SAN DIEGO, July 16, 2025--(BUSINESS WIRE)--Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation to ...
- Gemini normalized the inflammatory response at the cellular level in stage 3 and 4 CKD patients - - Gemini could potentially revolutionize the treatment of acute and chronic inflammatory disease - ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback